Lotus Bio-Technology Development (LBTD) Stock Statistics & Valuation Metrics
Total Valuation
Lotus Bio-Technology Development has a market cap or net worth of $783.00. The enterprise value is $8.07T.
- Market Cap
- $783.00
- Enterprise Value
- $8.07T
Share Statistics
Lotus Bio-Technology Development has 782,775,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 782,775,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Lotus Bio-Technology Development’s return on equity (ROE) is 0.32 and return on invested capital (ROIC) is 28.35%.
- Return on Equity (ROE)
- 0.32
- Return on Assets (ROA)
- 0.00
- Return on Invested Capital (ROIC)
- 28.35%
- Return on Capital Employed (ROCE)
- 0.24
- Revenue Per Employee
- ―
- Profits Per Employee
- ―
- Employee Count
- 0
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Lotus Bio-Technology Development is -50.00. Lotus Bio-Technology Development’s PEG ratio is 0.47.
- PE Ratio
- -50.00
- PS Ratio
- 0.00
- PB Ratio
- -13.50
- Price to FCF
- -454.12
- Price to Operating Cash Flow
- -46.62
- PEG Ratio
- 0.47
Income Statement
In the last 12 months, Lotus Bio-Technology Development had revenue of 0 and earned -19.55K in profits. Earnings per share was -0.00.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -19.55K
- Pretax Income
- -19.55K
- Net Income
- -19.55K
- EBITDA
- -18.46K
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was 263 and capital expenditures 0, giving a free cash flow of 18.02K billion.
- Operating Cash Flow
- 263
- Free Cash Flow
- 18.02K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
Lotus Bio-Technology Development pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -0.22%
- Earnings Yield
- -2.36%
Stock Price Statistics
- Beta
- 0.00
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
Lotus Bio-Technology Development as a current ratio of 0.00, with Debt / Equity ratio of -10.52%
- Current Ratio
- 0.00
- Quick Ratio
- 0.00
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.33
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Lotus Bio-Technology Development has paid 761.55K in taxes.
- Income Tax
- 761.55K
- Effective Tax Rate
- -38.95
Enterprise Valuation
Lotus Bio-Technology Development EV to EBITDA ratio is -437.17, with an EV/FCF ratio of -454.48.
- EV to Sales
- 0.00
- EV to EBITDA
- -437.17
- EV to Free Cash Flow
- -454.48
- EV to Operating Cash Flow
- -454.48
Balance Sheet
Lotus Bio-Technology Development has $50.01K in cash and marketable securities with $16.68K in debt, giving a net cash position of $33.32K billion.
- Cash & Marketable Securities
- $50.01K
- Total Debt
- $16.68K
- Net Cash
- $33.32K
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- ―
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Lotus Bio-Technology Development is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
